Show simple item record

dc.contributor.authorSchöffski, P
dc.contributor.authorWozniak, A
dc.contributor.authorCasali, P
dc.contributor.authorRutkowski, P
dc.contributor.authorBlay, J
dc.contributor.authorLindner, L
dc.contributor.authorStrauss, S
dc.contributor.authorAnthoney, A
dc.contributor.authorDuffaud, F
dc.contributor.authorRichter, S
dc.contributor.authorGrünwald, V
dc.contributor.authorLeahy, Michael G
dc.contributor.authorReichardt, P
dc.contributor.authorSufliarsky, J
dc.contributor.authorvan der Graaf, W
dc.contributor.authorSciot, R
dc.contributor.authorDebiec-Rychter, M
dc.contributor.authorvan Cann, T
dc.contributor.authorMarréaud, S
dc.contributor.authorLia, M
dc.contributor.authorRaveloarivahy, T
dc.contributor.authorCollette, L
dc.contributor.authorBauer, S
dc.date.accessioned2017-10-23T19:35:59Z
dc.date.available2017-10-23T19:35:59Z
dc.date.issued2017-09-18
dc.identifier.citationActivity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE". 2017, Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid28950372
dc.identifier.doi10.1093/annonc/mdx527
dc.identifier.urihttp://hdl.handle.net/10541/620617
dc.description.abstractClear cell sarcoma (CCSA) is an orphan malignancy, characterised by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor (TKI) crizotinib in patients with advanced or metastatic CCSA.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncologyen
dc.titleActivity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE".en
dc.typeArticleen
dc.contributor.departmentDepartment of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgiumen
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-04-03T11:41:38Z
html.description.abstractClear cell sarcoma (CCSA) is an orphan malignancy, characterised by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor (TKI) crizotinib in patients with advanced or metastatic CCSA.


Files in this item

Thumbnail
Name:
Activity and safety of crizotinib ...
Size:
52.97Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record